J Cancer Res Clin Oncol (2017) 143:1671–1677 DOI 10.1007/s00432-017-2416-4 ORIGINAL ARTICLE – CANCER RESEARCH 1 3 3 4 Bryan Oronsky · Tony R. Reid · Christopher Larson · Corey A. Carter · 4 5 2 Christina E. Brzezniak · Arnold Oronsky · Pedro Cabrales Received: 10 March 2017 / Accepted: 30 March 2017 / Published online: 17 April 2017 © Springer-Verlag Berlin Heidelberg 2017 Abstract spreads were prepared from whole bone marrow cells as Purpose RRx-001, a minimally toxic tumor-associated markers of clastogenicity. macrophage and neutrophil-repolarizing agent, is under Results RRx-001 pretreatment significantly decreased investigation in Phase II clinical trials as a sensitizer/resen- (P < 0.05) the blood urea nitrogen and creatinine levels. sitizer to cisplatin and carboplatin. On the basis of anecdo- A statistically significant ( P < 0.05) reduction in the mean tal clinical observations of improved platinum tolerability total chromosome aberration frequency per metaphase in following a priming period with RRx-001 as well as pre- the RRx-001 and cisplatin group compared to the cisplatin- clinical studies that have previously demonstrated radiopro- only group was observed. tection of intestinal stem cells and cardioprotection from Conclusions This study is the first to demonstrate that doxorubicin, the in vivo
Journal of Cancer Research and Clinical Oncology – Springer Journals
Published: Apr 17, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera